Fresenius Medical Care Corp Gets a Hold Rating from RBC Capital

By Ryan Adsit

In a report released today, Frank Morgan from RBC Capital reiterated a Hold rating on Fresenius Medical Care Corp (NYSE: FMS), with a price target of $44. The company’s shares opened today at $46.34, close to its 52-week high of $47.52.

According to TipRanks.com, Morgan is a 5-star analyst with an average return of 12.7% and a 64.0% success rate. Morgan covers the Healthcare sector, focusing on stocks such as Quest Diagnostics Inc, Surgery Partners Inc, and Envision Healthcare.

Fresenius Medical Care Corp has an analyst consensus of Moderate Buy, with a price target consensus of $44.

Fresenius Medical Care Corp’s market cap is currently $28.56B and has a P/E ratio of 20.79. The company has a book value ratio of 2.8096.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Fresenius Medical Care AG & Co. KGaA provides products and services for patients with chronic kidney failure. Its products include dialysis machines, dialyzers, and related disposables. It also offers renal information technology solutions and provides services such as renal replacement therapy and therapeutic apheresis. The company was founded on August 5, 1996 and is headquartered in Bad Homburg, Germany.